Investigation of Antifungal Properties of Synthetic Dimethyl-4-Bromo-1-(Substituted Benzoyl) Pyrrolo[1,2-a] Quinoline-2,3-Dicarboxylates Analogues: Molecular Docking Studies and Conceptual DFT-Based Chemical Reactivity Descriptors and Pharmacokinetics Evaluation.
Vijayakumar UpparSandeep ChandrashekharappaChandan ShivamalluSushma PKollur Shiva PrasadJoaquín Ortega-CastroJuan FrauNorma Rosario Flores-HolguínAtiyaparveen I BasarikattiMallikarjun ChougalaMrudula Mohan MGovindappa Banuprakashnull JayadevKatharigatta Narayanaswamy VenugopalaBelakatte P NandeshwarappaRavindra VeerapurAbdulaziz A Al-KheraifAbdhallah M ElgorbanAsad SyedKiran K Mudnakudu-NagarajuBasavaraj PadmashaliDaniel Glossman-MitnikPublished in: Molecules (Basel, Switzerland) (2021)
Candida albicans, an opportunistic fungal pathogen, frequently colonizes immune-compromised patients and causes mild to severe systemic reactions. Only few antifungal drugs are currently in use for therapeutic treatment. However, evolution of a drug-resistant C. albicans fungal pathogen is of major concern in the treatment of patients, hence the clinical need for novel drug design and development. In this study, in vitro screening of novel putative pyrrolo[1,2-a]quinoline derivatives as the lead drug targets and in silico prediction of the binding potential of these lead molecules against C. albicans pathogenic proteins, such as secreted aspartic protease 3 (SAP3; 2H6T), surface protein β-glucanase (3N9K) and sterol 14-alpha demethylase (5TZ1), were carried out by molecular docking analyses. Further, biological activity-based QSAR and theoretical pharmacokinetic analysis were analyzed. Here, in vitro screening of novel analogue derivatives as drug targets against C. albicans showed inhibitory potential in the concentration of 0.4 µg for BQ-06, 07 and 08, 0.8 µg for BQ-01, 03, and 05, 1.6 µg for BQ-04 and 12.5 µg for BQ-02 in comparison to the standard antifungal drug fluconazole in the concentration of 30 µg. Further, in silico analysis of BQ-01, 03, 05 and 07 analogues docked on chimeric 2H6T, 3N9K and 5TZ1 revealed that these analogues show potential binding affinity, which is different from the therapeutic antifungal drug fluconazole. In addition, these molecules possess good drug-like properties based on the determination of conceptual Density Functional Theory (DFT)-based descriptors, QSAR and pharmacokinetics. Thus, the study offers significant insight into employing pyrrolo[1,2-a]quinoline analogues as novel antifungal agents against C. albicans that warrants further investigation.
Keyphrases
- molecular docking
- candida albicans
- biofilm formation
- molecular dynamics simulations
- drug resistant
- density functional theory
- drug induced
- end stage renal disease
- chronic kidney disease
- multidrug resistant
- prognostic factors
- newly diagnosed
- mesenchymal stem cells
- molecular dynamics
- acinetobacter baumannii
- escherichia coli
- stem cells
- climate change
- single cell
- cell therapy
- binding protein
- early onset
- small molecule
- transcription factor
- bone marrow
- high resolution
- risk assessment
- combination therapy
- peritoneal dialysis
- amino acid
- structure activity relationship
- protein protein
- smoking cessation